Abstracts tagged "Intravenous Golimumab"

Abstract Number: 1204 • 2019 ACR/ARP Annual Meeting
Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial
M. Elaine Husni¹, Diane Harrison ², Elizabeth Hsia ³, Eric K H Chan ², Chenglong Han ², Shelly Kafka ⁴, Kim Hung Lo ², Lilianne Kim ² and Arthur Kavanaugh ⁵, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: In the randomized, phase 3, GO-VIBRANT study, more patients with psoriatic arthritis (PsA) achieved ACR 20/50/70 after 24 weeks IV treatment with the anti-TNFa…
Abstract Number: 1332 • 2019 ACR/ARP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Sergio Schwartzman¹, Aaron Broadwell ², Alan Kivitz ³, Shawn Black ⁴, Stephen Xu ⁵ and Shelly Kafka ⁶, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, RI, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 1552 • 2019 ACR/ARP Annual Meeting
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results Through Week 52 from a Phase-3 Study
Philip Mease¹, M. Elaine Husni ², Soumya Chakravarty ³, Shelly Kafka ⁴, Diane Harrison ⁵, Dennis Parenti ⁴, Lilianne Kim ⁵, Kim Hung Lo ⁵, Elizabeth Hsia ⁶ and Arthur Kavanaugh ⁷, ¹Swedish Med Center & U of Wash School of Med, Seattle, WA, ²Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ³Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: GO-VIBRANT is a Phase 3 trial of intravenous (IV) golimumab (GLM) in adult patients (pts) with active psoriatic arthritis (PsA). Clinically meaningful improvements in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].